Imago Biosciences, a portfolio business of early Investor Xeraya goes public

Imago Biosciences, a clinical-stage biopharmaceuticals business located in the United States, has priced its initial public offering (IPO) of 8,400,000 shares of common stock at US$16 per share.

Malaysian investor Xeraya first invested in Imago in April 2019, Fares Zahir, CEO of Xeraya Capital commented on the listing: “We are confident that Imago’s efforts will ease the suffering of patients in the not too distant future. Congratulations and much thanks to Hugh Rienhoff Jr and the team at Imago, and to Xeraya’s Imago’s team for their efforts in seeing this through.”

With offices in Kuala Lumpur and Boston, it is a worldwide life sciences investor.